Cardiff Oncology - CRDF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.50
  • Forecasted Upside: 346.81%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.35
▲ +0.1 (4.44%)

This chart shows the closing price for CRDF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardiff Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRDF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRDF

Analyst Price Target is $10.50
▲ +346.81% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cardiff Oncology in the last 3 months. The average price target is $10.50, with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 346.81% upside from the last price of $2.35.

This chart shows the closing price for CRDF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Cardiff Oncology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00Low
3/6/2024HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $14.00Low
3/1/2024Piper SandlerBoost TargetOverweight ➝ Overweight$5.00 ➝ $7.00Low
8/8/2023HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $13.00Low
5/9/2023HC WainwrightLower Target$15.00 ➝ $14.00Low
3/29/2023HC WainwrightReiterated RatingBuy$15.00Low
3/7/2023HC WainwrightBoost TargetBuy$14.00 ➝ $15.00Low
9/27/2022Robert W. BairdLower Target$6.00 ➝ $5.00Low
9/16/2022HC WainwrightLower TargetBuy$22.00 ➝ $14.00Low
9/13/2022Piper SandlerLower TargetOverweight$7.00 ➝ $5.00Low
8/29/2022Robert W. BairdLower TargetOutperform$9.00 ➝ $6.00Low
5/27/2022Piper SandlerLower Target$20.00 ➝ $7.00Low
5/10/2022Robert W. BairdLower Target$13.00 ➝ $9.00Medium
5/9/2022HC WainwrightLower Target$25.00 ➝ $22.00Low
4/12/2022HC WainwrightReiterated RatingBuy$25.00Medium
2/28/2022HC WainwrightLower TargetBuy$26.00 ➝ $25.00High
1/24/2022Maxim GroupLower Target$25.00 ➝ $14.00Low
1/5/2022William BlairInitiated CoverageOutperformMedium
12/7/2021Robert W. BairdInitiated CoverageOutperform$19.00High
11/19/2021Maxim GroupReiterated RatingBuy$24.00Medium
9/9/2021HC WainwrightReiterated RatingBuy$26.00High
9/9/2021Maxim GroupBoost TargetBuy$20.00 ➝ $25.00High
8/10/2021HC WainwrightBoost TargetBuy$25.00 ➝ $26.00Medium
8/9/2021Maxim GroupLower TargetBuy$30.00 ➝ $20.00Medium
6/9/2021HC WainwrightReiterated RatingBuy$25.00Medium
5/10/2021HC WainwrightLower TargetBuy$27.00 ➝ $25.00Medium
5/7/2021Maxim GroupReiterated RatingBuy$30.00Medium
1/19/2021HC WainwrightReiterated RatingBuy$27.00High
10/22/2020HC WainwrightInitiated CoverageBuy$27.00High
10/21/2020Maxim GroupBoost Target$14.00 ➝ $20.00High
10/8/2020Piper SandlerInitiated CoverageOverweight$25.00High
9/18/2020Maxim GroupBoost TargetBuy$6.00 ➝ $14.00Low
6/1/2020Maxim GroupInitiated CoverageBuy$6.00Low
5/29/2020Noble FinancialReiterated RatingBuy$23.00High
5/19/2020Maxim GroupInitiated CoverageBuy$6.00N/A
(Data available from 7/22/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
1/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/23/2024
  • 4 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/23/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cardiff Oncology logo
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.35
Low: $2.22
High: $2.38

50 Day Range

MA: $2.77
Low: $2.05
High: $3.74

52 Week Range

Now: $2.35
Low: $0.94
High: $6.42

Volume

261,301 shs

Average Volume

1,142,660 shs

Market Capitalization

$105.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiff Oncology?

The following Wall Street sell-side analysts have issued research reports on Cardiff Oncology in the last twelve months: HC Wainwright, and Piper Sandler.
View the latest analyst ratings for CRDF.

What is the current price target for Cardiff Oncology?

2 Wall Street analysts have set twelve-month price targets for Cardiff Oncology in the last year. Their average twelve-month price target is $10.50, suggesting a possible upside of 346.8%. HC Wainwright has the highest price target set, predicting CRDF will reach $14.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $7.00 for Cardiff Oncology in the next year.
View the latest price targets for CRDF.

What is the current consensus analyst rating for Cardiff Oncology?

Cardiff Oncology currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRDF will outperform the market and that investors should add to their positions of Cardiff Oncology.
View the latest ratings for CRDF.

What other companies compete with Cardiff Oncology?

How do I contact Cardiff Oncology's investor relations team?

Cardiff Oncology's physical mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The company's listed phone number is (858) 952-7570 and its investor relations email address is [email protected]. The official website for Cardiff Oncology is cardiffoncology.com. Learn More about contacing Cardiff Oncology investor relations.